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Abstract. Retinoic acid has been previously proposed in the treatment of Alzheimer’s disease (AD). Here, five transgenic
mouse models expressing AD and frontotemporal dementia risk genes (i.e., PLB2APP, PLB2TAU, PLB1Double, PLB1Triple, and
PLB4) were used to investigate if consistent alterations exist in multiple elements of the retinoic acid signaling pathway
in these models. Many steps of the retinoic acid signaling pathway including binding proteins and metabolic enzymes
decline, while the previously reported increase in RBP4 was only consistent at late (6 months) but not early (3 month) ages.
The retinoic acid receptors were exceptional in their consistent decline in mRNA and protein with transcript decline of
retinoic acid receptors  and  by 3 months, before significant pathology, suggesting involvement in early stages of disease.
Decline in RBP1 transcript may also be an early but not late marker of disease. The decline in the retinoic acid signaling
system may therefore be a therapeutic target for AD and frontotemporal dementia. Thus, novel stable retinoic acid receptor
modulators (RAR-Ms) activating multiple genomic and non-genomic pathways were probed for therapeutic control of gene
expression in rat primary hippocampal and cortical cultures. RAR-Ms promoted the non-amyloidogenic pathway, repressed
lipopolysaccharide induced inflammatory genes and induced genes with neurotrophic action. RAR-Ms had diverse effects on
gene expression allowing particular RAR-Ms to be selected for maximal therapeutic effect. Overall the results demonstrated
the early decline of retinoic acid signaling in AD and frontotemporal dementia models and the activity of stable and potent
alternatives to retinoic acid as potential therapeutics.
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INTRODUCTION
Alzheimer’s disease (AD) is a chronic multifacto-
rial neurodegenerative disorder that is characterized
by the accumulation of amyloid plaques and neurofib-
∗Correspondence to: Peter McCaffery, Institute of Medical Sci-
ences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD,
Scotland, UK. Tel.: +44 1224437362; E-mail: p.j.mccaffery@ab
dn.ac.uk.
rillary tangles, progressive memory impairment, and
the deterioration of cognitive ability [1]. It is the most
common cause of dementia and contributes to about
60% to 70% of all cases [2]. Today, approximately 47
million people have AD worldwide, and the number
is expected to reach more than 131 million by 2050
[3].
Retinoic acid (RA), the active metabolite of vita-
min A, is well studied from its role in development of
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the central nervous system (CNS), but more recently
evidence has accumulated on the importance of RA
signaling in the adult CNS [4]. The components of
the RA signaling system are present in the adult brain
such as the synthetic and catabolic enzymes, recep-
tors, and binding proteins, although the distribution
pattern differs from the one observed in the embry-
onic CNS [5]. RA is known to be crucial for several
aspects of neuroplasticity within the adult brain. Neu-
roplasticity is fundamental to the formation of new
memories [6], and aspects of neuroplasticity pro-
moted by RA are long-term potentiation/depression
(LTP/LTD) [7], neurogenesis [8], homeostatic plas-
ticity [9], and the capacity to form new neurites and
neurite extensions [10].
Use of RA for AD is suggested by findings such as
low endogenous retinol levels correlating with cogni-
tive decline in the aging human [11] and that RA falls
in the aging rodent brain [12, 13]. Mingaud et al. have
shown that age-related downregulation of RA signal-
ing disrupts hippocampal LTP and cellular properties,
and that retinol supplementation reverses the effects
[13]. Among the first proposal of a link between
retinoids and AD, Goodman and Pardee reported a
genetic linkage between AD and RA using the Locus
Link database, that showed a large number of genes
implicated in AD pathology are located at chromoso-
mal loci together with RA signaling system encoding
genes [14]. In addition, several studies reported
a decline in RA signaling in various AD models
[15].
As RA supports neuronal survival and neuroplas-
ticity, essential for learning and memory, this decline
weakens cognitive function [4]. If decreased RA
levels promote AD, it would be anticipated that
restoration of levels would be protective and sev-
eral in vitro studies have indicated that RA reduces
amyloid- (A) neurotoxicity [16, 17]. Furthermore,
it was shown that a vitamin A-deficient diet in rodents
leads to disruption in the RA signaling system and A
deposition in the cerebral blood vessels of forebrain
neurons, and that these changes were reversed by RA
administration [18, 19]. RA also inhibits the produc-
tion of different cytokines and chemokines, such as
interleukin 6 [20, 21], involved in the inflammatory
response of many age related diseases. For example,
the mRNA levels of interleukin 6 increase early in
the hippocampus and cortex of Tg2576 AD model
mice [22]. RA also inhibits many aspects of microglia
activation, such as tumor necrosis factor alpha pro-
duction and the expression of inducible nitric oxide
synthase [23]. Such anti-inflammatory actions of RA
will be beneficial for treatment of neurodegenerative
disease.
Boosting the RA signal with synthetic ligands
for its receptor improves cognition in transgenic
mouse models of AD, clearing A in both neurons
and microglia as well as providing a strong anti-
inflammatory action [24]. Hence, synthetic retinoids
may provide a treatment for AD and other neu-
rodegenerative disorders. Tamibarotene (Am80) is an
example of a synthetic retinoid that is studied exten-
sively as a candidate drug for AD because of its
various beneficial effects. Kawahara et al. reported
that administration of Am80 decreased the level of
insoluble A42 in APP23 AD model mice [25].
Am80 neuroprotective effects were also observed in
inflammation-induced midbrain neurons by increas-
ing brain-derived neurotrophic factor levels [26].
Acitretin is another retinoid drug currently studied.
Acitretin was reported to increase the levels of the
-secretase (ADAM10) of amyloid- protein precur-
sor (APP), driving the non-amyloidogenic pathway
in neuroblastoma cells with reduction in A lev-
els in APP/PS-1 AD model mice [27]. In addition,
Acitretin was reported to cross the blood-brain bar-
rier (BBB) in mice [28]. Endres et al. investigated
the changes in -secretase-derived APP (APPs-)
levels in the cerebrospinal fluid (CSF) of mild to mod-
erate AD patients after oral acitretin therapy. Results
showed that acitretin increased APPs- levels and
enhanced non-amyloidogenic APP processing in
human patients [29].
A significant problem with the study of demen-
tia/AD models is that most are only a model of a
single hypothesis for the cause of AD. A compre-
hensive understanding of the disease is necessary to
develop successful therapeutics that will tackle the
majority of cases. This study used multiple, geneti-
cally comparable transgenic knock-in mouse models
of AD, and models of tau pathology associated with
AD and frontotemporal dementia (FTD), to investi-
gate alterations in RA signaling at the gene and/or
protein level in these models. Hippocampal and cor-
tical mixed primary cultures from Sprague Dawley
rats were used as well to perform an initial test of the
therapeutic potential of a group of novel synthetic
retinoids (RAR-Ms) active with genomic and non-
genomic targets [30]. The capacity of these RAR-Ms
to beneficially activate or repress A processing
genes and anti-inflammatory/neuroprotective genes,
in primary neuron/glia cultures suggests retinoids
as a line of research of high potential for AD
treatment.
T. Khatib et al. / Retinoic Acid Defect in Alzheimer’s Disease 937
METHODS
Retinoid solutions
All-trans-RA (Sigma-Aldrich) was dissolved at
0.1 M in dimethyl sulfoxide (DMSO) under red light,
aliquoted and stored under N2 at –70 ◦C, protected
from light. Synthetic retinoids (RAR-Ms) were dis-
solved in DMSO to give 0.01 M stock solutions.
RAR-Ms were designed and synthesized as described
previously [31–37]. The molecular structures of the
RAR-Ms are shown in Fig. 1. The majority of the
compounds exhibit high affinity for the RA receptors
(RARs).
Transgenic animal models
Five types of transgenic knock-in mouse models of
in-house developed knock-in (PLB) mouse lines were
studied to determine if there are any defects in the RA
signaling system at the gene and/or protein levels. The
PLB1Double mouse model expresses human mutated
APP and Tau (human APP Swedish and London
mutations: K670N, M671L and V717I; human Tau
mutations: P301L and R406W). PLB1Triple expresses
human mutated APP, Tau, and PS1 and was created
by crossing the PLB1Double model with an existing
presenilin (PS1) mice (A246E) to get the three-gene
combination [38]. The two monogenic mouse models
APP (PLB2APP) [39] and Tau (PLB2TAU) were cre-
ated by crossing the double transgenic mouse model
PLB1Double with deleter mice (Flp or Cre expressing
mice that excise the FRT flanked or floxed regions
respectively) [40]. The fifth model, PLB4, expresses
human BACE1 [41]. The wild type (WT) control
animals (PLBWT) used in the study were generated
out of the parental PLB1Double, strain, followed by
multiple generation crossing with C57BL/6 (Harlan
Laboratories Ltd) from human APP and Tau nega-
tive littermates. All PLB mice were maintained on
the same C57BL/6 background.
Fig. 1. Molecular structures of the RAR-Ms used in the study.
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The PLBWT (n = 24 males and 4 females),
PLB2APP (n = 5 males and 1 female), PLB2TAU (n = 8
males), PLB1Double (n = 7 males and 5 females),
PLB1Triple (n = 5 males), and PLB4 (n = 6 males)
mice were killed at 6 months of age by cervical dislo-
cation, while PLBWT (n = 12 males), PLB2APP (n = 4
males), PLB2TAU (n = 12 males), and PLB1Double
(n = 7 males) mice were killed at 3 months age. The
brains were removed, snap frozen in liquid nitro-
gen, weighed, and stored in microtubes at –70◦C
until needed. Each frozen brain was cut along the
sagittal plane into two halves and one half was used
for ribonucleic acids (RNA) extraction and quantita-
tive polymerase chain reaction (qPCR) analysis work
while the other half was used for protein sample
preparation and western blotting analysis. Different
ratios of males and females were used in the study
of different mouse models which might differentially
influence the results. There is little published on the
influence of gender on RA signaling and so for two
different AD models, a wide variety of retinoid sig-
naling genes in the brain were compared between
genders. There was no significant difference between
males and females (Supplementary Figure 1).
Animals were bred at Charles River UK and deliv-
ered to the University of Aberdeen animal facility at
least one week before use. All animals were housed
and tested in accordance with UK Home Office, the
EU directive 63/2010E and the Animal (Scientific
Procedures) Act 1986.
Rat primary cultures
Sprague Dawley (SD) rat pups were used to pre-
pare primary neuron cultures. Rat primary cultures
were used because hippocampal neurons are more
numerous and faster maturing in rats than mice [42].
The rat pups were killed at postnatal day zero or one
(P0-P1) by cervical dislocation and the heads were
removed and placed on ice until dissection. The brains
were dissected within 1 h of cervical dislocation.
6-Well plates were coated with 1 ml of poly-
L-lysine (PLL; Sigma-Aldrich) solution at a final
concentration of 0.002%. The plates were incubated
for at least 2 h at 37◦C. Two thorough washes with
sterile PBS followed and afterwards the plates were
air dried in the cell culture hood and stored at 4 ◦C in
the fridge wrapped in parafilm until use.
The cortex and hippocampus from rat pup brains
were rapidly dissected on a sterile 35 mm culture
dish containing cold serum-free Neurobasal medium
(Thermo Fisher Scientific) within 1 h of the cer-
vical dislocation procedure. The collected tissues
were placed inside Bijou containers with Neurobasal
medium on ice. Following dissection as much Neu-
robasal medium as possible was removed leaving the
tissue at the bottom of the containers. Two ml of
0.05% trypsin-EDTA solution (Thermo Fisher Scien-
tific) were then added and the tubes were incubated
at 37 ◦C for 15 min. The trypsin was then removed
and replaced with the same volume of 1 mg/ml soy-
beans trypsin inhibitor (Thermo Fisher Scientific)
and the container incubated for 5 min at room tem-
perature. Afterwards, trypsin inhibitor was removed
and 3 ml of supplemented Neurobasal medium with
1% Glutamax (Thermo Fisher Scientific), 2% B27
without vitamin A (Thermo Fisher Scientific), and
1% penicillin-streptomycin (Thermo Fisher Scien-
tific) were added above the tissue of each of the tubes.
The tissue was gently triturated using a fire polished
glass Pasteur pipette and the cloudy medium con-
taining the dissociated cells was passed through a
40m cell sieve into 50 ml falcon collection tubes.
The process was repeated until the tissue was disso-
ciated completely. The cells were then centrifuged at
a relative centrifugal force (rcf) of 226 for 4 min at
room temperature using a Mistral 3000i centrifuge
(MSE) and resuspended in 2 ml of fresh supple-
mented Neurobasal medium. Cells were counted
using the TC10TM automated cell counter instrument
(Bio-Rad) by mixing 15l of 0.4% trypan blue with
15l of cell suspension in 0.6 ml microtube and then
adding 2×10l of the mix to the dual chamber cell
counting slides (Bio-Rad). After that, 30,000 cells
were plated per well and the media was changed every
2 days. The cells were used in experiments after 14
days in vitro (DIV).
Retinoid treatment of primary cultures
To examine the influence of RA and RAR-Ms on
the expression of a group of genes involved in AD,
the cells in wells were treated with RAR-Ms for 24 h
in triplicate. 24 h was chosen as the optimum treat-
ment time from a preliminary study comparing 6
and 24 h (Supplementary Figure 2). Each experiment
was repeated three times. RNA was then extracted
from treated cells for qPCR analysis. To examine
the influence of RA and other synthetic RAR-Ms on
inflammation, the cells were treated first with 1g/ml
lipopolysaccharide (LPS; Sigma-Aldrich) for 6 h to
induce inflammation followed by RA/RAR-Ms treat-
ment for 24 h. Subsequently, RNA was extracted from
the treated cells for qPCR analysis.
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Gene expression analysis
Total RNA was extracted from primary cultures
treated with 10 nM RAR-M for 24 h or frozen
half brain tissues of transgenic AD knock-in mouse
models using a Qiagen RNeasy mini kit according
to the manufacturer’s protocol. cDNA was synthe-
sized from 250 ng total RNA from cells or 500 ng
total RNA from tissues using High qScript cDNA
Synthesis master mix. qPCR reactions using Per-
feCTa SYBR Green SuperMix were performed on a
Roche LightCycler 480 and analyzed using LightCy-
cler 480 1.5 software. Primers were designed using
Primer-BLAST [43]. GenNorm primer kits were
used for housekeeping genes (PrimerDesign). Stan-
dard curves and blank controls were run for all sets
of primers tested. A housekeeping gene expression
experiment was carried out for each model, and the
data obtained were analyzed using the free RefFinder
software [44] to determine the best reference genes
for each experiment. RNA levels of target genes in
PLB models and rat cultures were normalized to
the appropriate reference RNA levels according to
each experiment and compared to levels in wild type
mouse model (PLBWT) or control untreated cells
(CT) which were set at 1. In 6-month-old PLB models
experiments, Gapdh and B2m reference genes were
used with PLB1Triple, Nono and Ywhaz were used
with PLB2APP and PLB2TAU, Gapdh and Ywhaz with
PLB1Double, and Gapdh and Rpl13a with PLB4. In 3-
month PLB models experiments, Ywhaz and Rpl13a
were used with PLB2APP, PLB2TAU, and PLB1Double.
Actb reference gene was used in rat cultures exper-
iments. The sequence of primers used is shown
in Table 1.
Protein analysis
Frozen half brain tissues of all male transgenic
PLB knock-in mouse models (4 PLBWT, 5 PLB2TAU,
and 5 PLB1Double) were homogenized mechanically
in NP-40 lysis buffer containing protease inhibitor
cocktail (Sigma-Aldrich, 10l per 1 mg) using man-
ual disposable pestles. Protein concentrations were
measured using a BCA assay kit (Thermo Fisher Sci-
entific). 30g protein was loaded and separated by
Table 1
Primer sequences for genes used in qPCR analysis
Primer Sequences
Gene Species Forward Primer (5’ −→ 3’) Reverse Primer (5’ −→ 3’)
Abca1 Rat TGTGGAATCGTCCCTCAGTT CATCGATGGTCAGCGTGTCA
Abcg1 Rat GGCCGCTTTCTCGGTCG TTCAGGTGCCCATTAAGCAGAT
Actb Rat CCACACCCGCCACCAGTTCG TACAGCCCGGGGAGCATCGT
Apoe Rat TCCCCTGCTCAGACCCC GTCACCTCCAGCTCTCCCT
App Rat GTTGAGCCTGTCGACGC AAGCCTGAATCATGTCCGAACT
Bace1 Rat CCGGCGGGAGTGGTATTATG CTTGGGCAAACGAAGGTTGG
Ccl5 Rat CCATATGGCTCGGACACCAC GCGGTTCCTTCGAGTGACAA
Ccl3 Rat TCCTATGGACGGCAAATTCCA CAGATCTGCCGGTTTCTCTTG
Crabp1 Mouse GGCGTTGGGTGTGAACGCCA GGCCAGCTCTCGGGTCCAGT
Crabp2 Mouse GATGGAGAGCTGATCCTGACAATGAC TGCTGACCTGGGAGGGGCAA
Rbp1 Mouse GCAAGTGCATGACCACTGTGAGC TTCGCTGGCAGAAGCCTGGG
Cyp26a1 Mouse GCCTGTACCGGGGCGTGAAG GTGACGTCGCAGCACTGGCT
Cyp26b1 Mouse CCAGGACTGTATGCCCATGA CCACTCACCAACAAAAAGACAAG
Ide Rat TAGCAGGCCTGAGCTATGATCT TGGCTGTTTGTCATTGTAACCT
Igf1 Rat GAAGCGATGGGGAAAATCAGCA CGAGCTGGTAAAGGTGAGCAA
Igf2 Rat GGAGGGGAGCTTGTTGACAC TATGTCTCCAGGAGGGCCAA
Il1b Rat GTGCAAGTGTCTGAAGCAGC CCCAAGTCAAGGGCTTGGAA
Il12a Rat GCCTGCTTACCACTGGAACT CCAAGGCACAGGGTCATCAT
Adam10 Rat CAAACGAGCAGTCTCACACG TGTCCCTCTTCATTCGTAGGT
Mme Rat TTGCACCGGGGTTCATTTG TTCTTCGGCTTTGGAGCATTG
Nos2 Rat GGACTTTTAGAGACGCTTCTGAG CTCTGAAGAGAAACTTCCAGGGG
Aldh1a2 Mouse CAAGGAGGCTGGCTTTCCACCC GGGCTCTTCCCTCCGAGTTCCA
Aldh1a3 Mouse TCAAAGAGGTCGGGTTCCCTCCG AGGCGGCTTCTCTGACCAGCT
Rar Mouse CGCCAAGGGAGCTGAACGGG GGGTGGCTGGGCTGCTTCTG
Rar Mouse ACACCACGAATTCCAGCGCTGAC CAGACCTGTGAAGCCCGGCA
Rar Mouse CCTGTGAAGGCTGCAAGGGCT GTCGGGCGAGCCCTCCTCTT
Rbp4 Mouse ACGAGTCCGTCTTCTGAGCAACTG GCACAGCTCCTCCTGCCGTT
Sod1 Rat AGGATTAACTGAAGGCGAGCA GGTCTCCAACATGCCTCTCTT
Stra6 Mouse TTGTGCTTCGGCAGGGCACC CTGGTCTGCAGCCCCTGGGA
Tnf Rat GATCGGTCCCAACAAGGAGG TTTGCTACGACGTGGGCTAC
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electrophoresis through 12% SDS-polyacrylamide
gels and transferred to nitrocellulose membranes.
Western blots were developed using enhanced chemi-
luminescence (Millipore) and the protein bands were
detected and scanned using a myECL Imager (Ther-
moScientific). The Ponceau S staining was used as a
loading control method. The levels of our proteins
of interest were normalized to total protein levels
rather than using a specific reference protein such
as-actin [45–49], because the housekeeping protein
levels may vary depending on disease state especially
in neuropathological events [50]. After normaliza-
tion, target protein levels were compared to protein
levels in wild type mouse models (PLBWT) which
were set at 1.
Western blot antibodies used are shown in
Table 2.
Statistical analysis
All data are presented as mean ± SEM. Samples
were run in triplicate and each experiment was also
run three times. Statistical analyses were performed
in Microsoft Office Excel 2017 or GraphPad Prism
7.0c version (Prism, GraphPad Software, San Diego,
CA). Gene expression and western blot data were ana-
lyzed by Student’s t-test or one-way ANOVA with
Newman-Keuls multiple comparison test as appro-
priate; P value < 0.05 was considered statistically
significant. ∗p ≤ 0.05, ∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001
RESULTS
Gene expression of key retinoic acid signaling
molecules in Alzheimer’s disease mouse models
The expression of RA signaling system genes was
screened first in brains from 6-month-old mice of the
five types of transgenic mouse models of AD and FTD
Fig. 2. Gene expression analysis of RA signaling system genes
in 6-month-old half brains of different AD and FTD transgenic
mouse models. RNA was isolated from half brains of AD and FTD
mouse models and analyzed by reverse transcription followed by
qPCR. A) RA receptors, B) RA enzymes, and C) retinol bind-
ing proteins. RNA levels were standardized with respect to the
appropriate reference RNA controls in each model and compared
to levels in wild type mouse models (WT) which were set at 1.
Data represent fold change in the mean of RNA levels with n≥ 6.
Error bars indicate standard error of the mean (SEM) (∗p≤ 0.5;
∗∗p≤ 0.01; ∗∗∗p≤ 0.001, one-way ANOVA with Newman-Keuls
multiple comparison test).
using a qPCR method to detect RNA levels (Fig. 2).
The models used were: PLB2APP knock-in model
that expresses mutations in APP [39], PLB2TAU
Table 2
List of antibodies used in western blotting
Primary Antibody Host Dilution Predicted Molecular Supplier (CAT#)
Weight
CYP26A1 Rabbit 1 : 200 56 kDa Source Bioscience (CYP26A11-A)
CYP26B1 Rabbit 1 : 500 58 kDa Proteintech (21555-1-AP)
RALDH1 Rabbit 1 : 1000 54 kDa Abcam (ab24343)
RALDH2 Rabbit 1 : 3000 55 kDa Millipore (ABN420)
RALDH3 Rabbit 1 : 500 53 kDa Millipore (ABN427)
RAR (C-20) Rabbit 1 : 1500 51 kDa Santa Cruz (sc-551)
RAR Rabbit 1 : 500 50 kDa Abcam (ab53161)
RAR (C-19) Rabbit 1 : 200 50 kDa Santa Cruz (sc-550)
RDH10 Rabbit 1 : 500 39 kDa Proteintech (14644-1-AP)
STRA6 (Q-14) Goat 1 : 200 74 kDa Santa Cruz (sc-138065)
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knock-in model that expresses mutations in Tau [40],
PLB1Double knock-in model that expresses mutations
in APP and Tau, PLB1Triple knock-in model that
expresses mutations in APP, Tau, and presenilin 1
[38], and the PLB4 knock-in model that expresses
human BACE1 [41]. The number of PLB mice used
for gene expression experiments at 6 months of
age was 28 PLBWT, 6 PLB2APP, 8 PLB2TAU, 12
PLB1Double, 5 PLB1Triple, and 6 PLB4.
The data indicated that the RNA levels of 2
subtypes of RARs ( and ) were downregulated
in all PLB models except PLB4 compared to
the wild type control mice (Fig. 2A). Rarβ was
downregulated by 60% in PLB2APP (p = 0.0413)
and PLB1Double (p = 0.0056), 80% in PLB2TAU
(p = 0.0013), 30% in PLB1Triple (p = 0.0419), and
40% in PLB4 (p = 0.0488), while Rarα was 66%
downregulated only in the PLB1Double model
(p = 0.0451). Rarγ was downregulated in 4 PLB
models, with the exception of PLB4, with a decline
of 36% in PLB2APP (p = 0.0354), 60% in PLB2TAU
(p = 0.0071), 75% in PLB1Double (p = 0.0009), and
27% in PLB1Triple (p = 0.0279). The expression
of RNA levels of two RA synthesizing enzymes
(Aldh1a2 and Aldh1a3) and two RA catabolizing
enzymes (Cyp26a1 and Cyp26b1) was also screened
in all PLB models (Fig. 2B). Aldh1a2 was down-
regulated by 74% in both PLB2APP (p = 0.021) and
PLB2TAU (p = 0.0198), while Aldh1a3 declined by
50% in PLB4 (p = 0.0491). Cyp26a1 was downregu-
lated by 40% in PLB2APP (p = 0.0252) and PLB2TAU
(p = 0.0249), and 50% in PLB1Double (p = 0.0105)
and PLB1Triple (p = 0.0118). Cyp26b1 levels declined
by 54% in PLB1Double (p = 0.0486) and 80% in PLB4
(p = 0.0052). The expression of three retinol binding
protein genes (Crbp1, Rbp4, and Ttr) was then
screened in the PLB models (Fig. 2C). Rbp4 RNA
was upregulated by 103% in PLB2APP (p = 0.0263),
248% in PLB2TAU (p = 0.0385), 69% in PLB1Double
(p = 0.0204), and 283% in PLB1Triple (p = 0.0007).
Rbp1 and Ttr RNA levels did not change in the
models.
Given the qPCR data confirmed that there were
abnormalities in the RA signaling system in AD ani-
mal models at 6 months of age, the expression of RA
related genes was determined at the earlier age of 3
months in PLB2APP, PLB2TAU, and PLB1Double PLB
models (Fig. 3). This tests for genetic changes before
significant pathology is evident in the brain of these
mice [38, 40]. The number of PLB mice used for gene
expression experiments at 3 months of age was 12
PLBWT, 4 PLB2APP, 12 PLB2TAU, and 7 PLB1Double.
Fig. 3. Gene expression analysis of RA signaling system genes
in 3-month-old half brains of different AD and FTD transgenic
mouse models. RNA was isolated from half brains of AD mouse
models and analyzed by reverse transcription followed by qPCR.
A) RA receptors, B) RA enzymes, and C) RA binding proteins.
RNA levels were standardized with respect to the appropriate ref-
erence RNA controls in each model and compared to levels in wild
type mouse models (WT) which were set at 1. Data represent fold
change in the mean of RNA levels of at least six mouse models.
Error bars indicate standard error of the mean (SEM) (∗p≤ 0.5,
one-way ANOVA with Newman-Keuls multiple comparison test).
Analysis of the expression of different RA-related
genes indicated that the RA signaling system was also
altered in 3-month-old PLB models. The RNA lev-
els of two RAR subtypes ( and ) showed a pattern
of downregulation in almost all PLB models, with
approximately 35% to 40% decline in Rarβ and Rarγ
RNA levels (Fig. 3A). Then, RNA levels of Aldh1a2,
Aldh1a3, Cyp26a1, and Cyp26b1 were screened in
PLB models (Fig. 3B). Aldh1a2 was downregulated
by 40% in PLB1Double (p = 0.0339). Cyp26a1 was
downregulated by 65% in PLB2TAU (p = 0.0361),
while Cyp26b1 was declined by 42% and 57% in
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PLB2TAU (p = 0.0439) and PLB1Double (p = 0.0198)
lines, respectively. Surprisingly Aldh1a3 RNA was
upregulated by 110% in both PLB2TAU (p = 0.0495)
and PLB1Double (p = 0.0108). The RNA levels of
three retinol binding protein genes (Rbp1, Rbp4, and
Ttr), a RA binding protein (Crabp1) gene and a
retinol binding protein receptor gene (Stra6) were
also screened in the PLB models (Fig. 3C). The RNA
level of Rbp4 was increased by 150% in PLB1Double
(p = 0.0478) mice. Stra6 RNA did not change in the
PLB2APP model, but it was apparently downregulated
in the PLB2TAU (40%) and PLB1Double (50%) mod-
els, with a significant decrease evident in the latter
(p = 0.0468). Ttr decreased by 33% in PLB1Double
(p = 0.0348). Crabp1 RNA did not change in the PLB
models. The Rbp1 RNA was downregulated by 60%
in PLB2TAU (p = 0.0495) and 70% in PLB1Double
(p = 0.0297).
In summary, the expression of a group of RA sig-
naling pathway genes was investigated in 6- and
3-month-old transgenic mice to identify deficits in
the RA signaling system. Data indicated that the
RNA levels of the RA signaling system were abnor-
mally expressed. RARs, in particular , , as well
cyp26 enzymes were downregulated. Other genes
were more specifically changed, for instance RBP4
RNA levels were upregulated in all tested models at
6 months but did not change at 3 months while RBP1
transcripts decreased only at 3 months.
Protein expression of key retinoic acid signaling
molecules in Alzheimer’s disease mouse models
After investigating the RNA levels of genes encod-
ing the RA signaling system, samples were available
to determine RA signaling protein levels in 6-month-
half brains of the PLB2TAU and PLB1Double models
using the western blot technique. These two models
were focused on as those changing most consistently
in transcript levels. The number of PLB mice used
for protein expression experiments at 6 months of
age was 4 PLBWT, 5 PLB2TAU, and 5 PLB1Double.
The three subtypes of RAR (, , ) were down-
regulated in all AD mice models compared to the
wild type control mice (Fig. 4A). RAR was down-
regulated by 17% and 30% in PLB2TAU (p = 0.013)
and PLB1Double lines (p = 0.0037), respectively.
RAR was only downregulated by 40% in the
PLB1Double model (p = 0.0288). RAR levels were
reduced in PLB2TAU by 36% (p = 0.0484). The
protein levels of several of the RA synthesiz-
ing/degrading enzymes along with RBP4 receptor
STRA6 were also screened in the PLB models
(Fig. 4B). RDH10 (retinol dehydrogenase enzyme for
synthesizing retinal from retinol) did not change in
PLB models. RALDH2 and STRA6 proteins were
upregulated in some PLB models, with the former
being increased by 200% in PLB1Double (p = 0.0002)
and the latter by 157% in PLB2TAU (p = 0.0186).
Fig. 4. Western blot analysis of RA signaling system proteins in 6-month-half brains of different AD and FTD transgenic mouse models.
50g proteins from half brains tissue lysate of PLB mouse models were analyzed by western blot for A) RA receptors or B) RA enzymes
and STRA6 proteins and quantified using ImageJ software. Proteins of interest were normalized to total proteins levels measured using
Ponceau S staining and compared to protein levels in wild type mouse models (WT) which were set at 1. Shown are mean values of at
least four mouse models. Error bars indicate standard error of the mean (SEM) (∗p≤ 0.5; ∗∗p≤ 0.01; ∗∗∗p≤ 0.001, one-way ANOVA with
Newman-Keuls multiple comparison test).
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CYP26B1 was downregulated by 43% in PLB1Double
(p = 0.0295).
In summary, the levels of RA signaling pathway
proteins were investigated in 6-month-old transgenic
mice to determine if there were any deficits in this
system at the protein level. The RARs (, , ) were
the most consistently downregulated, while STRA6
levels were upregulated in all tested models.
Inﬂuence of synthetic retinoids on expression of
retinoic acid-related AD genes in mixed
neural/glial primary cultures
The decline in RA signaling in varied PLB mod-
els supports the concept of this pathway as a target
for AD treatment. A new group of ligands for the
RARs have been developed called RAR-Ms, initially
screened for dual genomic and non-genomic activity
[30]. As an initial genomic test of the RAR-Ms to reg-
ulate genes in a beneficial way for AD treatment, 17
genes either directly associated with AD, or provid-
ing neuroprotection or acting in an anti-inflammatory
fashion, were initially tested on rat hippocampal and
cortical mixed primary neural/glial cultures. Cultures
were treated with a series of RAR-M compounds at
10 nM concentration after 14 DIV for 24 h and RNA
levels were measured by the qPCR technique. For
each experiment, 3 wells of 6-well plate were used
per RAR-Ms treatment, and each experiment was
repeated three times.
The effect of RAR-Ms on the RNA levels of
amyloid processing genes was first examined in cor-
tical and hippocampal mixed primary cultures. The
AD related genes examined for RAR-Ms regulation
were: Neprilysin (Mme), insulin degrading enzyme
(Ide), A disintegrin and metalloproteinase domain-
containing protein 10 (Adam10), amyloid precursor
protein (App), and -site amyloid precursor protein
cleaving enzyme 1 (Bace1). These genes were previ-
ously reported to be regulated by RA [24, 51–54].
In cortical cultures (Fig. 5A) the RNA levels of
the Mme gene were significantly upregulated by
DC528 and DC645 compared to both RA and the
control, while DC526, DC716, and DC719 increased
Mme levels significantly compared to the control
only. DC525, DC540, and DC527 significantly down-
regulated the expression of Mme gene. Ide was
upregulated significantly by RA, EC23, DC525,
DC526, DC528, DC716, DC719, and DC645. DC645
induction of Ide was significant compared to RA as
well. App was significantly upregulated by EC23,
DC526, DC528, and DC719. Adam10 was upreg-
Fig. 5. qPCR analysis of amyloid processing genes in primary hippocampal and cortical cultures treated with RAR-Ms. Primary rat cortical
(A) and hippocampal (B) cultures were treated with 10 nM RAR-M for 24 h. RNA was isolated and analyzed by reverse transcription
followed by qPCR. Amyloid processing gene RNA levels were standardized with respect to the Actb RNA control and compared to levels
in control untreated cells (CT) which were set at 1. Shown are mean values of three biological replicates analyzed in triplicate. Error bars
indicate standard error of the mean (SEM) (∗p≤ 0.05; ∗∗p≤ 0.01, ∗∗∗p≤ 0.001, one-way ANOVA with Newman-Keuls multiple comparison
test).
944 T. Khatib et al. / Retinoic Acid Defect in Alzheimer’s Disease
ulated significantly by DC528, DC716, DC719,
DC526, and DC645, with the latter two compounds
also being significantly greater than RA. Bace1 was
significantly upregulated by DC719 and downregu-
lated by DC525.
In hippocampal cultures (Fig. 5B), Mme was sig-
nificantly upregulated by DC526, DC528, DC645,
and DC716 with this increase being significant
compared to RA and the control. DC525 treat-
ment significantly downregulated Mme levels. Ide
was significantly upregulated by EC23, DC528,
DC645, DC716, and DC719. DC525 treatment down-
regulated Ide gene levels. App levels increased
significantly with EC23 and DC645 treatments.
Adam10 RNA levels increased in EC23, DC526,
DC528, DC645, and DC716 significantly. Bace1
was downregulated by DC540, DC527, DC526, and
DC528.
In addition, the effect of RAR-Ms on the expres-
sion of genes involved in neuroprotection was
investigated in rat primary cultures (Fig. 6). The neu-
roprotection related genes examined for RAR-Ms
regulation were: two ATP-binding cassette (ABC)
transporters A1 and G1 (Abca1 and Abcg1), the Cu-
Zn superoxide dismutase (Sod1), and apolipoprotein
E (Apoe). These genes were previously reported to
be regulated by RA [55–57].
From analysis of cortical culture data (Fig. 6A)
RNA levels of Abca1 were significantly upregulated
by all RAR-Ms except DC540, while DC526 and
DC645 were shown to be more effective than RA.
Abcg1 was upregulated by DC525, DC527, DC645,
and DC719, with the latter three compounds being
more efficacious than RA. Sod1 gene was induced to
a notable extent by DC526, DC528, DC645, DC716,
and DC719, and Apoe levels were shown to be
increased by treatment with DC525 and DC527 treat-
ments.
In the case of hippocampal cultures (Fig. 6B),
Abca1 was upregulated by DC526, DC528, DC645,
DC716, and DC719 compared to control and RA,
while DC527 increased Abca1 compared to control
only. Abcg1 was upregulated significantly by DC526
and DC719 compared to RA and the control. Sod1
RNA was induced by all RAR-Ms except EC23.
All RAR-Ms treatments induced Apoe, with DC528
exhibiting particularly effective activity compared to
both RA and the control.
The effect of the RAR-Ms on the expression of
genes involved in neuroinflammation and neuropro-
tection was then examined in the primary cultures.
The inflammation related genes examined for regula-
tion by the RAR-M compounds were: two C-C motif
chemokine ligands, number 3 and 5 (Ccl3 and Ccl5),
tumor necrosis factor alpha (Tnf), and inducible nitric
oxide synthase (Nos2) as well as two types of inter-
leukins 12 and 1 beta (Il-12 and Il-1). In addition,
two neuroprotective growth factors were examined,
Fig. 6. qPCR analysis of neuroprotection genes in primary hippocampal and cortical cultures treated with RAR-Ms. Primary cortical (A)
and hippocampal (B) cultures were treated with 10 nM RAR-M for 24 h. RNA was isolated and analyzed by reverse transcription followed
by qPCR. RNA levels were standardized with respect to the Actb control and compared to levels in control untreated cells (CT) which were
set at 1. Neuroprotective genes were upregulated by RAR-M treatment. Shown are mean values of three biological replicates analyzed in
triplicate. Error bars indicate standard error of the mean (SEM) (∗p ≤ 0.05; ∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001 one-way ANOVA with Newman-Keuls
multiple comparison test).
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Fig. 7. qPCR analysis of inflammation regulated genes in primary
hippocampal and cortical cultures treated with LPS. Primary cor-
tical (A) and hippocampal (B) cultures were treated with 1g/ml
LPS for 6 h to induce inflammation. RNA was isolated and ana-
lyzed by reverse transcription followed by qPCR. Inflammatory
gene expression was standardized with respect to the Actb RNA
control and compared to levels in control untreated cells (CT)
which were set at 1. The expression of all genes was upregulated
during inflammation except Igf1 which was downregulated signif-
icantly in hippocampal cultures. Shown are mean values of three
biological replicates analyzed in triplicate. Error bars indicate stan-
dard error of the mean (SEM) (∗p ≤ 0.05; ∗∗p ≤ 0.01, student’s
t-test).
insulin growth factor 1 and 1 (Igf1 and Igf2). These
genes have all been reported to be regulated by RA
previously [23, 58, 59].
Mixed primary neuronal and glial cultures were
first treated with 1g/ml LPS for 6 h to induce inflam-
mation (Fig. 7). LPS treatment induced the expression
of all inflammation related genes significantly in the
cortex cell culture, except for Igf1. In hippocampal
cultures, all genes were also upregulated except for
Igf1 and Igf2. Igf1 levels were reduced significantly
in hippocampal cultures after LPS treatment. Ccl5
was the gene induced to the greatest extent during
inflammation followed by Nos2 and Il-1β.
After the induction of inflammation, the expres-
sion of these inflammation related genes was screened
in the primary cultures treated with synthetic RAR-
Ms to determine how the expression of these genes
changed in response to the RAR-M compounds.
In cortical cultures (Fig. 8), all RAR-Ms decreased
the RNA levels of the Ccl3 gene except EC23. Ccl5
was downregulated by RA, DC526, DC528, DC645,
DC716, and DC719 significantly. Tnf was downregu-
lated by all RAR-Ms except RA, DC525, and DC716,
with DC645 being the most effective. Nos2 RNA
levels were downregulated by all RAR-Ms except
DC716. Il-1 was notably upregulated by EC23
and, in contrast, downregulated by DC540, DC526,
DC528, DC645, DC716, and DC719, with DC526
and DC716 being significantly more effective com-
pared to RA. Il-12 RNA levels were upregulated by
all RAR-Ms. Igf1 RNA levels were increased signif-
icantly by all RAR-Ms except DC527, DC526 and
DC719. Treatment with RA, EC23, DC525, DC645,
and DC716 caused a significant upregulated in Igf2
gene expression.
In hippocampal cultures (Fig. 9), all RAR-Ms
decreased the RNA levels of the Ccl3 gene except
EC23 and DC525. Ccl5 was downregulated by all
RAR-Ms except DC540 and DC526, with DC527,
DC528, and DC645 being significantly more effec-
tive compared to RA. Tnf was downregulated by RA,
DC719, DC526, DC528, and DC645, with the lat-
ter three compounds being more effective than RA.
Nos2 and Il-1 RNA levels were downregulated by
RA, DC527, DC526, DC528, DC645, DC716, and
DC719. Il-12 and Igf1 RNA levels were upregulated
by RA, DC526, DC528, DC645, DC716, and DC719.
Igf2 was significantly induced by all RAR-Ms except
RA, DC540, and DC527, compared to both control
and RA.
In summary, novel RAR-Ms were screened for
their ability to regulate the expression of 17 genes
involved in either amyloid processing, neuroprotec-
tion, or neuroinflammation in rat mixed primary
cultures. These initial tests of the therapeutic poten-
tial of RAR-Ms indicated that different ligands had
varied effects on the investigated genes and DC526,
DC528, and DC645 were more effective than RA in
regulating almost all genes in a therapeutically bene-
ficial way. Other RAR-Ms had beneficial effects, but
on a limited number of genes and not all of them such
as DC540 and DC527 while RAR-Ms such as DC525
regulated some genes in the opposite direction to most
ligands.
DISCUSSION
It is well recognized that the complex pathology
of dementias such as AD means it cannot be ade-
quately studied in a single animal model, as they
are largely based on a single hypothesis, and usu-
ally rely on rare genetic mutations detected in AD
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Fig. 8. qPCR analysis of inflammation regulated genes in primary cortical cultures treated with LPS followed by RAR-Ms. Primary cortical
cultures were treated with 1g/ml LPS for 6 h to induce inflammation, and then with 10 nM RAR-M for 24 h. RNA was isolated and analyzed
by reverse transcription followed by qPCR. Inflammatory genes were standardized with respect to the Actb RNA control and compared to
levels in control untreated cells (CT) which were set at 1. The expression of all genes was downregulated after RAR-M treatment except for
Il-12, Igf2, and Igf2 which were upregulated. Shown are mean values of three biological replicates analyzed in triplicate. Error bars indicate
standard error of the mean (SEM) (∗p ≤ 0.05; ∗∗p ≤ 0.01, one-way ANOVA with Newman-Keuls multiple comparison test).
Fig. 9. qPCR analysis of inflammation regulated genes in primary hippocampal cultures treated with LPS and RAR-Ms. Primary hippocampal
cultures were treated with 1g/ml LPS for 6 h to induce inflammation, and then with 10 nM RAR-M for 24 h. RNA was isolated and analyzed
by reverse transcription followed by qPCR. Inflammatory genes were standardized with respect to the Actb RNA control and compared to
levels in control untreated cells (CT) which were set at 1. The expression of all genes was downregulated after RAR-M treatment except
Il-12, Igf2, and Igf2 which were upregulated. Shown are mean values of three biological replicates analyzed in triplicate. Error bars indicate
standard error of the mean (SEM) (∗p ≤ 0.05; ∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001, one-way ANOVA with Newman-Keuls multiple comparison test).
(APP, BACE, presenilin) or FTD (tau) patients. There
is also a need to examine the contribution of indi-
vidual genes versus bi- or trigenic models of AD
[60]. Several studies have investigated the changes
in retinoid signaling in over-expression models, but
none have so far investigated genetically comparable
models [61], expressing mutated tau and/or APP as
well as BACE1, in knock-in models. It has here been
demonstrated that endogenous RA signaling changes
differentially in five different transgenic PLB mouse
lines, at the gene and/or protein level. Genes encoding
components of the RA signaling system were abnor-
mally expressed in these mouse models at 6 months of
age. Further, analysis of gene expression in 3-month-
old mice illustrated early deficits in RA signaling,
such as the reduction of Rarβ and Rarγ receptors
in all PLB models and the decline in Cyp26b1 and
Rbp1 in both PLB2TAU and PLB1Double models. This
is indicative that such changes may be an initiator
event in AD.
The three subtypes of RA receptors (, , ) were
downregulated in the PLB models at both RNA and
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protein levels and this decrease will lead to an almost
inevitable fall in the strength of RA signal in the brain.
The link between vitamin A and dementia had been
made by Corcoran and colleagues who reported that
Rarα was downregulated in the forebrain of 6-month-
old vitamin A deficient rats accompanied by a loss
of choline acetyltransferase (ChAT) and followed by
A deposition in 1-year-old VAD rats [19]. It was
also reported that Rarβ and/or Rxr null mice exhibit
impairment in LTP and working memory [7] and
that there is an approximately 30% decline in Rarβ
and Rxr/ expression in the hippocampus of aged
mice [62]. Furthermore, pathological samples from
AD patients showed Rarα deficits along with A
deposition in the surviving neurons in the meningeal
vessels of the neocortex [19]. These results imply that
a decline in RA receptors may be among the events
initiating AD.
The initial catalyst resulting in an early decrease in
expression of the RA receptors is unknown. One pos-
sibility is that this is an indicator of an early decline in
RA levels in the brain. All RARs are inducible by RA
[63, 64] and in particular RAR  and  in the CNS
[19] can decline when RA levels fall. A clue to what
triggers the fall in RA may lie in the role microglia
have in brain RA metabolism. Activation of microglia
increases their capacity to degrade RA [65], possibly
part of the inflammatory response to AD, while A
is able to inhibit RA synthesis, potentially blocking
microglia RA synthetic capacity [24]. It is of note that
decline in RAR expression and RA signaling is also
evident in the aging mouse and that this is reversible
by RA treatment [66]. Although the cognitive decline
in AD and normal aging each has its distinguishable
features, there is also significant overlap between the
two in genetic susceptibility and epigenetic input [67,
68]. Epigenetic modification has been proposed in the
treatment of both AD [69] and aging [70]. This may
be another mechanism by which RA can influence
cognitive decline and aging given the capacity of RA
to regulate epigenetic change [71].
Changes in other RA signaling components,
enzymes, and binding proteins were more complex
in the PLB models suggesting that they may be
secondary to the decline in the RA receptors or
secondary to other events in the AD brain. The
Aldh1a2 gene encoding the enzyme that synthe-
sizes RA was downregulated at the RNA level in
6-month-old PLB2APP and PLB2TAU PLB models
and 3-month-old PLB1Double PLB model, but sur-
prisingly it was upregulated at the protein level at
6 months. The increase in RALDH2 protein could
be a feedback/compensatory mechanism at the trans-
lational level in order to increase RA synthesis in
response to the decline of RA signal. A similar phe-
nomenon was described in the neuroblastoma cell
line LA-N-5, where RALDH was increased when the
cells were depleted in RA and was restored to nor-
mal levels on addition of RA [72]. It is of particular
note that there is a two-fold increase in the RALDH
protein in the hippocampus and parietal cortex of
AD patients [72]. Further, an increase in RALDH2
protein was reported in the spinal cord of rats dur-
ing inflammation [73, 74], and one of the features
of AD is inflammation. This may be a key interact-
ing event leading to the increase of RALDH2 in the
AD mouse models, regulating at a translational level
despite the decrease in Aldh1a2 transcript. It has been
reported in a number of studies that mRNA and pro-
tein expression levels do not always correlate [75,
76] and this is also the case for the retinoid signal-
ing system in the adult brain [77]. Several factors
could influence the mRNA-protein correlation such
as posttranscriptional and posttranslational modifi-
cations, mRNA and protein stability, protein half-life
and the lower rate of transcription compared to trans-
lation in mammalian cells.
The RA catabolizing enzymes (CYP26A1 and
CYP26B1) were both downregulated at the RNA and
protein levels in all our PLB models. Both these
genes are reliant on RA for induction as a regula-
tory mechanism to protect against excess RA and
their expression falls when RA is low [78–81]. Their
decline in the PLB mice may reflect the overall reduc-
tion in RA signaling in the AD/FTD brain.
RBP4 is a liver secreted retinol carrier protein in the
circulation [82]. Its function in the brain is unknown
but an increase in RBP4 protein levels was reported in
the brain of APP/PSEN1 AD model mice [83], and it
is upregulated in the liver and forebrain of 8-month-
old PLB4 mice [84]. The current study reproduced
these findings and Rbp4 gene levels were upregu-
lated in the brains of all 6-month-old PLB models
but at 3 months only in the PLB1Double mouse line.
High levels of RBP4 protein have been found in the
amyloid plaques of human AD patients [85]. Par-
ticularly intriguing is the correlation of decreasing
RBP4 in the CSF with progression of normal to mild
cognitive impairment to AD, suggesting a movement
of RBP4 between brain compartments with disease,
although this study was with a small patient pool [86].
Changes in RBP4 may be part of the metabolic disor-
der linked with AD [87] and the inconsistent change
between mouse models at 3 months in RBP4 tran-
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script suggests that this may not be an early change
in disease.
Alterations in STRA6, the RBP4 cell surface
receptor [88], may also be part of these metabolic
disruptions in AD. STRA6 changed in a complex
fashion, being downregulated at the RNA level but
upregulated at the protein level in PLB2TAU and
PLB1Double AD mouse models (Fig. 4). STRA6
acts as a cell surface signaling receptor activat-
ing the JAK2/STAT5 signaling transduction pathway
following RBP4/retinol binding which induces the
expression of suppressor of cytokine signaling 3
(SOCS3) protein, which in turn inhibits insulin sig-
naling [89]. CRBP1 is part of the STRA6 complex
on the intracellular side and assists with transport of
retinol into the cell and sites of its use [88], and is
also linked to metabolic disorders [90]. Rbp1 gene
expression levels were downregulated in 3-month-
old PLB2TAU and PLB1Double PLB models. Thus, the
overexpression of STRA6 along with the upregulated
RBP4 levels in the brain and downregulated CRBP1
on the intracellular side of the receptor might jointly
interrupt movement of retinol into cells and dysregu-
late metabolism in AD. Furthermore, TTR, a carrier
protein for retinol and thyroxine in the plasma and
CSF [91], was decreased in 3-month-old PLB1Double
at the gene level. Lower levels of TTR protein were
reported previously in the CSF of AD patients [92].
The animals used are refined AD models with
low expression of AD-related genes and the stud-
ies presented here on prodromal stages of disease
add to the accumulating evidence that RA signal-
ing declines early in neurodegeneration leading to
the proposal of the use of RAR ligands as therapeu-
tics to boost RA signaling [93]. There is currently
preliminary pilot data on the use of retinoids in clin-
ical trials, but the potential therapeutic effects of
retinoids in AD are still at an early stage of investi-
gation. For example, the results of the clinical trial of
bexarotene (RXR agonist) suggests that it may reduce
brain amyloid and increases serum A1–42 in ApoE4
noncarriers in mild to moderate AD patients [94].
Moreover, acitretin (RAR agonist) entered Phase II
clinical trials in Germany in 2010, and the preliminary
results reported 25% increase in APPs- in CSF of
mild to moderate AD patients in the treatment group
[29].
In this study, we have provided an initial test of a
new RAR-M class of retinoid, selected by screening
for both genomic and non-genomic activity, the drugs
were tested on primary neuron/glia mixed cultures
from hippocampus and cortex. The RAR-Ms tested
herein are significantly more chemically stable than
RA, which can be easily oxidized and isomerized in
the presence of light, oxidants, and excessive heat
[95, 96]. The RAR-M family is exemplified by EC23
[33] which has been shown to be 8-fold greater in
potency (EC50) than RA in genomic activity (acti-
vation of a retinoic acid response element), while
exhibiting similar non-genomic (activation of ERK
kinase) potency (EC50) to RA [30].
Several studies had already shown the involve-
ment of RA signaling in amyloid pathology. RA
deficiency leads to A accumulation in the cerebral
cortex and blood vessels [18, 19] and a group of
amyloid processing proteins is upregulated by RA,
including BACE1 [51], APP [52], ADAM10 [53],
IDE, and NEP [24, 53]. Induction of these proteins
by RA will be therapeutically advantageous, with the
conspicuous exception of BACE1 in which induc-
tion could potentially worsen the disease. In this new
study, RA, along with a group of synthetic RAR-
M compounds, upregulated the amyloid processing
genes. Of the tested compounds, RAR-Ms DC526,
DC528, and DC645 were more effective at inducing
Mme, Ide, and Adam10 in both cortical and primary
neurons compared to control, with no or weak induc-
tion or downregulation of Bace1. DC528 and DC645
induction of Mme was notably stronger compared to
RA in both cortical and primary neurons. DC526 and
DC645 increased Adam10 in cortical neurons com-
pared to RA. It was also notable that although these
RAR-Ms were selected according to their potent
genomic and non-genomic biological activities, there
was significant variance in the genes they activated;
for instance, DC525 reduced the levels of genes such
as Mme, which is disadvantageous in the treatment of
AD.
RA has neuroprotective properties since it low-
ers cholesterol levels by upregulating the expression
of genes involved in cholesterol homeostasis, such
as Abca1 and Abcg1 [56]. These ABC cholesterol
transporters play a role in the lipidation of ApoE,
the protein involved in the transport of cholesterol to
neurons via low density lipoprotein receptors, which
promotes the clearance of A [97–99]. The RAR-M
compounds were shown to upregulate the expression
of Abca1, Abcg1, and Apoe involved in cholesterol
regulation and neuroprotection, with DC526, DC528,
and DC645 being significantly stronger compared to
RA in most cultures. Regulation of cholesterol home-
ostasis is important for synaptic transmission and
neural plasticity [100], and excess cholesterol levels
promote the generation of A [101].
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Other neuroprotective genes investigated included
Sod1, the encoded protein known to bind copper and
zinc ions and quench free superoxide radical species
in the body. There are elevated levels of oxidative
stress in AD patients and transgenic mouse mod-
els of AD [102, 103] and APP and A impair
mitochondrial import channels and electron transport
chain, leading to the generation of free reactive oxy-
gen species [104]. Sod1 was notably upregulated by
DC526, DC528, DC645, and DC716 compared to the
control in both cortical and hippocampal cultures.
The ability of the RAR-Ms to suppress an LPS
induced inflammatory reaction was also investigated
in the mixed neuronal/glial cultures, adding the RAR-
M after inflammation was induced for 6 hours.
Neuroinflammation has been proposed to play a role
in AD and elevation in inflammatory response and
mediators is associated with cognitive decline and
loss of neurons in AD patients and transgenic ani-
mal models of AD [105, 106]. Microglia act to clear
A through phagocytosis; however, this interaction
activates signaling cascades which, in turn, mediate
the release of different pro-inflammatory cytokines
(TNF, IL-1, etc.), chemokines (CCL3, CCL5,
etc.), and reactive oxygen/nitrogen species which fur-
ther promotes A plaques [107, 108]. Each of the
RAR-Ms downregulated the expression of multiple
genes involved in inflammation whether in cortical
or hippocampal cultures such as Ccl3, Ccl5, Tnf,
Nos2, and Il-1, with DC526, DC528, and DC645
being significantly more effective compared to RA
in decreasing these inflammatory markers in most
cultures. Surprisingly though, RAR-Ms upregulated
Il-12 gene expression. It was reported previously that
IL-12 may have anti-inflammatory activity [109].
Moreover, the regulation of this interleukin might
depend on choosing the right treatment time, as it can
fall and then rise following the induction of inflam-
mation [110].
LPS induced inflammation may also promote neu-
rodegeneration through control of the expression
of growth factors. In hippocampal cultures, LPS
repressed both Igf1 and Igf2 (although markedly
inducing Igf2 in cortical cultures reminiscent of the
effect of LPS on human microglia [111]). IGF1 and
IGF2 modulate the survival of neurons and protect
against cytokine mediated death of neurons in human
neuronal cultures [111]. IGF1 increases -secretase
processing of APP and decreases A levels [112].
IGF1 and IGF2 have both been proposed as treat-
ments for AD [113–115]. Several of the RAR-Ms
upregulated the expression of both Igf1 and Igf2genes
and by increasing endogenous levels of the growth
factors, this circumvents the major problem of IGF1
or IGF2 treatment—poor BBB permeability. Small
lipophilic ligands for RARs generally cross the BBB
[28, 116], while RAR ligands like Am80 [117] and
acitretin [118] have demonstrable therapeutic action
in AD mouse models, indicative of their capacity to
cross the BBB.
Overall, this study strengthens the argument of
decreased RA signaling in early AD and the sub-
sequent dysregulation of the RA signaling system,
which could contribute to the underlying pathogen-
esis. The earliest consistent change in all models
examined was in RA receptors at both RNA and
protein level, and these may be earliest changes fol-
lowing the onset of tau and amyloid dysregulation.
The many other alterations in genes involved in RA
signaling may be secondary and in part compen-
satory. For instance, the change in RALDH2 may,
like CYP26A1 and CYP26B1, be a result of feedback
regulation of the RA signaling system, or alterna-
tively may be a response to inflammation. Changes
in RBP4, STRA6 and CRBP1, associated with vita-
min A’s role in metabolic disease [87] may be linked
with the metabolic abnormalities that occur in AD
[119].
The initial test of the therapeutic potential of RAR-
Ms found that DC526, DC528, and DC645 had a
strong anti-inflammatory effect downregulating most
inflammation genes more effectively than RA. They
would be expected to have neuroprotective activity
as they induced the expression of both Igf1 and Sod1.
DC526, DC528, and DC645 regulate APP process-
ing in a beneficial way, inducing Mme and Adam10
to a greater extent than RA and also inducing Ide,
but having a lower effect on Bace1 than RA. Sev-
eral other RAR-Ms also had beneficial effects on a
more limited number of genes – these were more
potent than RA but did not have the broader positive
effects of DC526, DC528, and DC645. For example,
DC540 and DC527 effectively repressed inflamma-
tory genes but also downregulated Mme and Ide
which are important for degrading A. Such RAR-
Ms may have future potential to be used to target
specific pathways.
Of the ligands for RA receptors investigated as
AD therapeutics the most interest has been directed
towards bexarotene, an agonist of retinoid X recep-
tors (RXR) which are related to the RARs but with
a wider range of action because they heterodimerize
with many nuclear receptors including PPAR, thyroid
hormone receptor, vitamin D receptors and others,
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including RAR. After the initial promise [55], not
all initial findings were replicated [120] but contin-
ued research suggests that bexarotene may still have
benefit as a therapeutic [121]. An important route of
action is the clearance of A by upregulating ApoE
levels [55]. Of the RAR-Ms investigated herein, a few
significantly upregulated Apoe levels, such as DC525
in cortical neurons and DC528 in hippocampal neu-
rons. However, there are a number of adverse effects
including cardiovascular risk due to hypertriglyc-
eridemia [122]. In comparison, the specificity of the
RAR-Ms for a single nuclear receptor should reduce
side-effects and the variety of therapeutic actions of
these drugs to be anti-inflammatory, neuroprotective,
and promote the non-amyloidogenic pathway, sug-
gesting promise in the future for treatment of AD
and other neurodegenerative diseases.
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